Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all blog posts
5.29.2019

Study Confirms Link Between Diabetes Drugs and Flesh-Eating Bacteria

By Brian Lynch
In The News

Adverse effects from prescription drugs are extremely common, ranging from relatively minor inconveniences like dry mouth and drowsiness to serious complications that seem worse than the patient’s underlying condition. But while many patients are willing to risk common drug side effects, some are decidedly uncommon. This is the case with a class of type-2 diabetes drug, as a new study confirms a link between SGLT2 inhibitors and flesh-eating bacteria known as Fournier’s gangrene.

Back in August we reported on an FDA warning that it had discovered multiple cases of Fournier’s gangrene in patients taking SGLT2 inhibitors like Janssen Pharmaceutical’s drug Invokana. At the time, only 12 cases of Fournier’s gangrene were discovered in patients taking SGLT2 inhibitors. A new study, published in the Annals of Internal Medicine, confirmed significantly more cases of Fournier’s gangrene in patients receiving SGLT2 inhibitors.

Fournier’s gangrene, also known as necrotizing fasciitis of the perineum, is a rare bacterial infection that attacks the genital region and perineum. This infection of the genitals and scrotum usually gets into the body via a cut or break in the skin and infects tissue that surrounds the muscles, nerves, fat, and blood vessels of the perineum. The infection spreads quickly and destroys the tissue.

Researchers combed through the FDA’s Adverse Event Reporting System and published case reports to compile their research. Between March 1, 2013 and January 31, 2019, they identified 55 unique cases of Fournier’s gangrene linked to SGLT2 inhibitors in patients ranging from age 33 to 87.

According to the study, the onset of Fournier’s gangrene after initiating SGLT2 inhibitor treatment varied from 5 days to 49 months. All affected patients were extremely ill and underwent surgical debridement to remove the unhealthy tissue.

The study also reports that several patients experienced additional complications, including diabetic ketoacidosis, sepsis, acute kidney injury, and infection of lower extremities which required amputation. Three patients died as a result of Fournier’s gangrene.

The study concludes that Fournier’s gangrene is a newly identified safety concern in patients taking SGLT2 inhibitors for type-2 diabetes, and doctors should be aware of the possible complications and early warning signs.

This isn’t the first time SGLT2 inhibitors like Invokana have been linked to adverse effects. Patients have reported kidney failure and impairment, urinary tract infections, and diabetic ketoacidosis. In 2017, the FDA required a black box warning for the type-2 diabetes medication canagliflozin (Invokana, Invokamet, etc.) due to an increased risk of leg and foot amputations.

Anyone taking SGLT2 inhibitors should be aware of the early warning signs of Fournier’s gangrene, which include tenderness, redness, or swelling of the genital region, fever exceeding 100.4 degrees Fahrenheit, dehydration, and anemia. Patients should contact their doctor immediately if they suspect they may have Fournier’s gangrene.

 

Share

No Comments

Leave a Reply Cancel reply

Receive News Updates

Get the latest from Wexler Wallace LLP & stay informed.

Categories

  • Media Appearances
  • Uncategorized
  • Columns
    • Guest Post
    • Ken Wexler
    • Ed Wallace
  • Practice Areas
    • Consumer Protection
    • Mass Tort Litigation
    • Business & Commercial Litigation
    • Healthcare Litigation
    • Employment Litigation
  • Cases
  • Hall Of Shame
    • Villain Of The Week
  • In The News
    • Public Victories
  • Featured Investigations
  • The Firm
    • News releases
    • Around The World
    • Our Professionals
    • Chicago
  • You Should Know
    • For Investors
    • For Businesses
    • For Consumers
  • Featured Cases
  • awards
  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP